Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Alzheimer’s drug rejected
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
Alzheimer’s drug donanemab for use in the country's national health service (NHS). The National Institute for Health and Care Excellence (NICE), which sets drug policy for the NHS, issued a draft guidance on Wednesday,
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
England’s drug-cost regulator rejected Eli Lilly’s Alzheimer’s drug for use in the country’s public health system, marking the second time a treatment for the disease has been deemed too costly.The U.
Eli Lilly Sues Over Knock-Off Weight-Loss Drugs
Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their drug, Zepbound.
NBC New York
1d
Cramer's Lightning Round: ‘Wait for a pullback' with Eli Lilly
Eli
Lilly
: "I would not buy the stock at this level. I would wait for a pullback." Dutch Bros: "I like the situation." ...
1d
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
STAT
1d
Senators demand answers on telehealth platforms from Pfizer and Eli Lilly
Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...
12h
Eli Lilly announces MHRA grants marketing authorization for donanemab
Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...
7d
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
8d
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
The Art Newspaper
4h
Smithsonian receives $40m from the Lilly Endowment
The Smithsonian Institution has received $40m from the Lilly Endowment for its upcoming celebrations of the 250th anniversary ...
FiercePharma
10h
Red light, green light: England's NICE not sold on Lilly's Kisunla despite UK approval
Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Alzheimer's disease
Zepbound
New York Stock Exchange
Food and Drug Administration
United Kingdom
Feedback